If the expression and/or activity of the ABC transporters which promote efflux of Aβ from the brain or reduce its entrance into the brain could be increased therapeutically in AD patients, this might lower brain levels of soluble Aβ (and by doing so, perhaps the aggregation of Aβ to form SPs would be reduced). The gene discussed is ABCG2; the disease is Alzheimer disease.